These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 84103)

  • 21. [Diffusion of gentamicin and tobramycin in the plasma and ascitic fluid of cirrhotic patients. Influence of the route of administration].
    Lapalus P; Bertrand F; Chabert JM; Bocquet JP; Delmont J
    Therapie; 1983; 38(3):247-54. PubMed ID: 6612661
    [No Abstract]   [Full Text] [Related]  

  • 22. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis.
    Bragonier R; Brown NM
    J Antimicrob Chemother; 1998 Jul; 42(1):103-6. PubMed ID: 9700537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
    Hennig S; Holthouse F; Staatz CE
    Clin Pharmacokinet; 2015 Apr; 54(4):409-21. PubMed ID: 25403847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Kinetics of tobramycin in newborn infants in intensive care].
    Guillois B; Guedes Y; Le Guen E; Le Bot MA; Riche C; Alix D
    Pathol Biol (Paris); 1986 May; 34(5):346-8. PubMed ID: 3534704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacokinetics of tobramycin (Brulamycin) in young and old age].
    Ludwig E; Arr M; Magyar T; Graber H
    Orv Hetil; 1982 Sep; 123(38):2357-9. PubMed ID: 7145401
    [No Abstract]   [Full Text] [Related]  

  • 26. [Experimental and clinical studies on tobramycin by intravenous drip infusion in the field of urology (author's transl)].
    Okayama S; Tsukamoto T; Nishio A; Sakai S; Kumamoto Y
    Jpn J Antibiot; 1981 Sep; 34(9):1235-43. PubMed ID: 7328748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
    Wang X; Koehne-Voss S; Anumolu SS; Yu J
    J Pharm Sci; 2017 Nov; 106(11):3402-3409. PubMed ID: 28634121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Central nervous system infections in pediatric hydrocephalus--intraventricular tobramycin therapy (author's transl)].
    Yamada H; Kageyama N; Nakamura S
    No Shinkei Geka; 1979 Jun; 7(6):571-8. PubMed ID: 471168
    [No Abstract]   [Full Text] [Related]  

  • 29. Tobramycin serum levels and tissue content in children.
    Daschner F
    Chemotherapy; 1977; 23(5):293-8. PubMed ID: 908234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis.
    Latzin P; Fehling M; Bauernfeind A; Reinhardt D; Kappler M; Griese M
    J Cyst Fibros; 2008 Mar; 7(2):142-6. PubMed ID: 17766190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Sensitivity of clinical isolates in the surgical field to aminoglycoside and clinical evaluation of tobramycin intravenous drip infusion (author's transl)].
    Iwai S; Jinno D; Yamamoto E; Yokota T; Okamura N; Takai K; Sato T; Kunimatsu M; Sakabe T
    Jpn J Antibiot; 1981 Oct; 34(10):1355-65. PubMed ID: 7334574
    [No Abstract]   [Full Text] [Related]  

  • 32. Therapeutic effect of topical antibiotic on untreated eye in experimental keratitis.
    Davis SD; Sarff LD; Hyndiuk RA
    Can J Ophthalmol; 1978 Oct; 13(4):273-6. PubMed ID: 105787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aspects of the pharmacology and toxicology of tobramycin in animals and humans.
    Israel KS; Welles JS; Black HR
    J Infect Dis; 1976 Aug; 134 Suppl():S97-103. PubMed ID: 787452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic results and tolerance of tobramycin in childhood].
    Lo Iacono F; Malizia R; Agnello D; Maltese I
    Pediatria (Napoli); 1979 Mar; 87(1):91-103. PubMed ID: 514747
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical studies on tobramycin for infectious diseases following intravenous drip infusion (author's transl)].
    Nakamura T; Hashimoto I; Sawada Y; Mikami J; Bekki E; Kasai Y; Nakanishi M; Katoh H; Matsuda S
    Jpn J Antibiot; 1981 Aug; 34(8):1158-72. PubMed ID: 7321194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detectable Concentrations of Inhaled Tobramycin in Critically Ill Children Without Cystic Fibrosis: Should Routine Monitoring Be Recommended?
    Miller JL; Lepa TM; Ranallo C; Chaaban H; Skrepnek GH; Johnson PN
    Pediatr Crit Care Med; 2017 Dec; 18(12):e615-e620. PubMed ID: 29206744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myoclonus associated with intraperitoneal imipenem.
    Lau KK; Kink RJ; Jones DP
    Pediatr Nephrol; 2004 Jun; 19(6):700-1. PubMed ID: 15052466
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
    Protzko E; Bowman L; Abelson M; Shapiro A;
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
    Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo inactivation of tobramycin by ticarcillin. A case report.
    Chow MS; Quintiliani R; Nightingale CH
    JAMA; 1982 Feb; 247(5):658-9. PubMed ID: 6798229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.